B
086040
vs
K
KOSPI 200
Over the past 12 months, Biotoxtech Co Ltd has underperformed KOSPI 200, delivering a return of -20% compared to KOSPI 200's +150% growth.
Stocks Performance
086040 vs KOSPI 200
Performance Gap
086040 vs KOSPI 200
Performance By Year
086040 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Biotoxtech Co Ltd
Glance View
Biotoxtech Co Ltd is a contract research company that helps drug makers and biotech firms test whether new medicines and chemicals are safe. It runs nonclinical studies such as toxicity testing, safety pharmacology, and related preclinical research that are needed before a product can move into human trials. Its customers are mainly pharmaceutical companies, biotech startups, and other life science firms that need outside expertise and lab capacity. The company makes money by charging fees for each study or project it performs. Clients pay Biotoxtech to design the test plan, run the experiments, analyze the results, and prepare the technical reports required by regulators and development teams. This makes the business more like a specialist service provider than a drug developer: it does not rely on selling a medicine to patients, but on selling research work to companies advancing their own products. Biotoxtech’s role in the industry is important because safety testing is a required step in drug development and can be difficult to do well in-house. By focusing on toxicology and preclinical evaluation, it sits early in the life sciences value chain and supports customers before clinical trials begin. That gives the company a steady B2B model tied to the pace of pharmaceutical and biotech development rather than consumer demand.
